Primary pharmacologic target defined by fused partner domain (Fused Partner Target)

The term 'Primary pharmacologic target defined by fused partner domain' refers to a classification of therapeutic targets where the pharmacological activity is dictated by a specific domain within a chimeric or fusion protein. These proteins typically arise from chromosomal translocations, such as the BCR-ABL1 fusion in chronic myeloid leukemia or EML4-ALK in non-small cell lung cancer. In these instances, the 'fused partner domain' (e.g., the kinase domain of ABL1 or ALK) becomes the primary site for drug intervention, often leading to constitutive activation of downstream signaling pathways. Targeting these fusions allows for high precision, as the oncogenic driver is unique to the malignant cells. However, this classification is a descriptive category rather than a single biological entity, encompassing a wide variety of kinase fusions, transcription factor fusions, and other chimeric drivers across different cancer types.

Other names

Fusion protein targetChimeric protein targetPartner-defined target

Inhibition of the chimeric protein's signaling or enzymatic activity driven by the fused domain.